Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2− pN0 early breast cancers

被引：0

作者：

Marie Viala

Marie Alexandre

Simon Thezenas

Pierre-Jean Lamy

Aurélie Maran-Gonzalez

Marian Gutowski

Pierre-Emmanuel Colombo

Gilles Romieu

William Jacot

Severine Guiu

机构：

[1] Institut Régional du Cancer de Montpellier - Val d’Aurelle,

[2] Institut Médical d’Analyse Génomique,undefined

[3] Labosud et Unité de Recherche Clinique,undefined

[4] Clinique Beau Soleil,undefined

[5] INSERM U1194–IRCM (Institut de Recherche en Cancérologie de Montpellier),undefined

来源：

Breast Cancer Research and Treatment | 2017年 / 165卷

关键词：

uPA/PAI; 1; Adjuvant chemotherapy; Breast cancer; Tailoring;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：611 / 621

页数：10

共 20 条

[1] Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2-pN0 early breast cancers
Viala, Marie
Alexandre, Marie
Thezenas, Simon
Lamy, Pierre-Jean
Maran-Gonzalez, Aurlie
Gutowski, Marian
Colombo, Pierre-Emmanuel
Romieu, Gilles
Jacot, William
Guiu, Severine
BREAST CANCER RESEARCH AND TREATMENT, 2017, 165 (03) : 611 - 621
[2] Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2-pN0 early breast cancer adjuvant treatments decision-making
Viala, M.
Alexandre, M.
Thezenas, S.
Lamy, P-J
Bibeau, F.
Gutowski, M.
Colombo, P-E
Romieu, G.
Jacot, W.
Guiu, S.
CANCER RESEARCH, 2017, 77
[3] Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer
Saadoun, Haidar
Lamy, Pierre-Jean
Thezenas, Simon
Pouderoux, Stephane
Bibeau, Frederic
Montels, Frederic
Romieu, Gilles
Colombo, Pierre-Emmanuel
Gutowski, Marian
Jacot, William
FUTURE ONCOLOGY, 2014, 10 (02) : 195 - 209
[4] Expression of invasive markers (uPA/PAI-1) in four different HER2, ER, PR subgroups of early breast cancer
Ravnik, M.
Takac, I.
Arko, D.
Goricek, B.
Sikocek, N. Cas
Lampelj, M.
Ravnik, J.
Cufer, T.
EJC SUPPLEMENTS, 2008, 6 (07): : 185 - 186
[5] Enhancing decision-making about adjuvant chemotherapy in ER+, HER2-early breast cancer (EBC) following EndoPredict testing
Fallowfield, L.
May, S.
Matthews, L.
Jenkins, V.
Mackay, J.
Arbon, A.
Hack, B.
Hall, J.
Harper-Wynne, C.
Hinde, S.
Moss, A.
Thanopoulou, E.
Westwell, S.
Wlaszly, D.
Simcock, R.
Patel, G.
Bloomfield, D.
ANNALS OF ONCOLOGY, 2017, 28
[6] Adjuvant therapy for HER2 positive pT1a-b pN0 breast cancer A single center cohort study
Yang, Xuan
Qu, Chong Xiao
MEDICINE, 2022, 101 (25) : E29371
[7] Prognostic significance of uPA/PAI-1 level, HER2 status, and traditional histologic factors for survival in node-negative breast cancer patients
Dovnik, Nina Fokter
Takac, Iztok
RADIOLOGY AND ONCOLOGY, 2017, 51 (01) : 65 - 73
[8] Prospective comparison of uPA/PAI-1 and EndoPredict-clin score in ER-positive, HER2-negative breast cancer: impact on risk stratification and treatment decisions
Etti, Johannes
Lackmann, Kirsten Grosse
Hapfelmeier, Alexander
Klein, Evelyn
Paepke, Stefan
Petry, Christoph
Specht, Katja
Hoefier, Heinz
Kiechle, Marion
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[9] Prospective comparison of conventional clinicopathological factors, uPA/PAI-1 and EndoPredict®-clin score (EPclin) for adjuvant clinical decision making in ER-positive, HER2-negative breast cancer: Progesterone receptor expression is strongly associat
Ettl, Johannes
Lackmann, Kirsten Grosse
Hapfelmeier, Alexander
Klein, Evelyn
Paepke, Stefan
Petry, Christoph
Specht, Katja
Wolff, Laura
Hoefler, Heinz
Kiechle, Marion
CANCER RESEARCH, 2015, 75
[10] Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers
Musolino, Antonino
Boggiani, Daniela
Sikokis, Angelica
Rimanti, Anita
Pellegrino, Benedetta
Vattiato, Rosa
Sgargi, Paolo
Falcini, Fabio
Caminiti, Caterina
Michiara, Maria
Leonardi, Francesco
CANCER TREATMENT REVIEWS, 2016, 43 : 1 - 7

← 1 2 →